# Protagonist Therapeutics, Inc (PTGX) — Stock CV

Protagonist Therapeutics, Inc is a $9.25B healthcare company. Revenue grew 612.4% over the last year, and it keeps 30¢ of every dollar of sales as profit. It trades at 112.2× earnings — in the most expensive third of its own history.

> Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases.

## Identity

- **Ticker**: PTGX
- **Sector**: Healthcare
- **Industry**: Pharmaceutical Preparations
- **Headquarters**: NEWARK, CA
- **Employees**: 141
- **Website**: https://www.protagonist-inc.com
- **Market cap**: $9.25B
- **Last price**: $143.00
- **Financial profile**: Strong

## Vitals (TTM)

- **Revenue**: $275M
- **Net income**: $82.9M
- **Free cash flow**: $131M
- **P/E**: 112.2
- **Revenue growth (YoY)**: 612.4%

## Skills (profile scores, 0–100)

| Pillar | Score |
|---|---|
| Valuation | 10 |
| Growth | 20 |
| Profitability | 57 |
| Health | 50 |
| Quality | 35 |
| Moat | 0 |

## Qualifications (beginner checklist) — 6 of 10 passed

- [x] Revenue growing — +612.4% YoY
- [x] Profitable — $82.9M TTM
- [ ] Profit growing — -147.3% YoY
- [x] Generates cash — $131M TTM
- [x] Debt under control — current ratio 21.71
- [x] Established company — $9.25B market cap
- [ ] Not printing shares — +29.6% shares over ~5y
- [ ] Proven track record — 1/10 profitable years
- [x] Financially stable — Altman Z 139.5 — safe
- [ ] Valuation not extreme — P/E 112.2

## Experience (career milestones)

- **FY2024** — Turned profitable: $275M net income after a loss year
- **FY2024** — Best year on record: $275M net income

## Strengths

- Strongly profitable — 30.2% net margin
- Revenue growing 612.4% year over year
- Strong cash conversion — FCF is 47.6% of revenue
- Altman Z-Score 139.54 — low bankruptcy-risk zone

## Watch-outs

- Thin interest coverage (-7.3×)
- Loss-making in 9 of the recent years

## Track record

| Year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| FY2021 | — | -$126M | -$109M |
| FY2022 | — | -$127M | -$109M |
| FY2023 | — | -$79.0M | -$70.8M |
| FY2024 | — | $275M | $183M |
| FY2025 | — | -$130M | $56.1M |

---

Source: https://stockcv.com/PTGX — derived from company filings; may be delayed or incomplete. Information, not investment advice.